Yep - good to hear another voice besides Diamond.
More talk about collaboration - this reinforces ideas expressed here that we'll see 'combination' therapy in the US.
$100m market cap is still a great entry point.
Feel good that Dr Price and Goolsbee are steering the ship.
Sarepta gene therapy study missed key target in Duchennes, page-339
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $21.40K | 203.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 215964 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 341886 | 4 |
View Market Depth
| Last trade - 10.06am 07/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |